@article {Yang2021.02.27.21252592, author = {Hyun Mo Yang and Luis Pedro Lombardi Junior and Ariana Campos Yang}, title = {Evaluating the trade-off between transmissibility and virulence of SARS-CoV-2 by mathematical modeling}, elocation-id = {2021.02.27.21252592}, year = {2021}, doi = {10.1101/2021.02.27.21252592}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background At the beginning of 2020, SARS-CoV-2 spread to all continents, and since then, mutations have appeared in different regions of the world. The appearance of more virulent mutations leads to asseverate that they are also more transmissible. We analyzed the lower and higher virulent SARS-CoV-2 epidemics to establish a relationship between transmissibility and virulence based on a mathematical model.Methods A compartmental mathematical model based on the CoViD-19 natural history encompassing the age-dependent fatality was applied to evaluate the SARS-CoV-2 transmissibility and virulence. The transmissibility was measured by the basic reproduction number R0 and the virulence by the proportion of asymptomatic individuals. The model parameters were fitted considering the observed data from S{\~a}o Paulo State.Results The numbers of severe CoViD-19 and deaths are three times higher, but R0 is 25\% lower in more virulent SARS-CoV-2 transmission than in a less virulent one. However, the number of more virulent SARS-CoV-2 transmitting individuals is 25\% lower, mainly due to symptomatic individuals{\textquoteright} isolation, explaining the increased transmission in lower virulence.Conclusions The quarantine study in S{\~a}o Paulo State showed that the more virulent SARS-CoV-2 resulted in a higher number of fatalities but less transmissible than the less virulent one. One possible explanation for the number of deaths surpassing that predicted by the low virulent SARS-CoV-2 infection could be the transmission of more virulent variant(s).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research received no specific grant from any funding agency, commercial or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NoneAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are openly available in "SP contra o novo coronavirus (Boletim completo)" at https://www.seade.gov.br/coronavirus/. https://www.seade.gov.br/coronavirus/}, URL = {https://www.medrxiv.org/content/early/2021/03/01/2021.02.27.21252592}, eprint = {https://www.medrxiv.org/content/early/2021/03/01/2021.02.27.21252592.full.pdf}, journal = {medRxiv} }